S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction.
The clinical results and changes in sputum found in both a short-term inpatient trial and a subsequent long-term outpatient investigation (three-month double-blind controlled study) of 82 patients with chronic bronchitis treated with a new mucolytic agent, S-carboxymethylcysteine (Mucodyne), are reported. Fluidification of sputum with reduction in certain measurements of the viscosity of morning sputum aliquots, associated with improvement in the ability to cough up bronchial secretions, significant increase in sputum volume output, and improvement in ventilation (as estimated by the forced expiratory volume in one second), were observed in both trials as dose-related responses, with an increase in the ease of expectoration and a reduction in cough frequency and dyspnea. Therapy with S-carboxymethylcysteine was well tolerated, and there were no serious adverse effects, either immediate or delayed. We suggest that the effect of the drug in fluidifying sputum may be due to a mucoregulatory mechanism which reverses the sputum macromolecular disturbances seen in chronic bronchitis.
D000284:Administration, Oral; D000328:Adult; D001991:Bronchitis / Q000188:drug therapy*; D002233:Carbocysteine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000031:analogs & derivatives*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006813:Humidity; D008297:Male; D008875:Middle Aged; D012138:Respiratory Therapy; D013183:Sputum / Q000187:drug effects*; D014783:Viscosity; D014797:Vital Capacity
D002233:Carbocysteine; D003545:Cysteine